Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) said its focus is now on preventative diagnostics as it looks to become a “leading aggregator” of innovative technology and tests.
The health diagnostics firm said in a third-quarter trading update that it will focus on blood and genetic testing alongside other services at its 258 clinics, including ear wax removal.
“The range of opportunities to develop our proposition in this exciting growth market to support the NHS and help people have better health outcomes are very exciting,” said chief executive Marc Howells.
“This direction of travel is one we embrace and look forward to delivering in the post-covid UK."
In the nine months to 30 September 2022, the AQSE Growth Market-listed company said revenue fell 6% compared to 2021 to £9.29mln, largely due to reduced but ongoing Covid testing delaying the roll-out of other tests.
Gross profit in the year-to-date also slipped 16% to £4.46mln, “reflecting the competitive environment”, a statement said.
As a result, it said the expected outcome for the end of the year will be lower than anticipated due to the current economic client, a squeeze on consumer spending and lead time for new products.
The group delisted from the Canadian Stock Exchange on 17 August, moving the company’s base to Guernsey and relisting on the AQSE Growth Market, with a dual listing in New York.